Marina Keul

List of Publications by Year in descending order

14 papers	509 citations	1039406 9 h-index	1058022 14 g-index
14 all docs	14 docs citations	14 times ranked	883 citing authors

#	Article	IF	Citations
1	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	5.8	107
2	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry, 2015, 58, 6844-6863.	2.9	92
3	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. Journal of Medicinal Chemistry, 2017, 60, 5613-5637.	2.9	77
4	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	5.8	55
5	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 2361-2372.	2.9	43
6	Lessons To Be Learned: The Molecular Basis of Kinaseâ€Targeted Therapies and Drug Resistance in Nonâ€Small Cell Lung Cancer. Angewandte Chemie - International Edition, 2018, 57, 2307-2313.	7.2	36
7	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chemical Science, 2019, 10, 10789-10801.	3.7	25
8	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 7725-7744.	2.9	24
9	Characterization of Covalent-Reversible EGFR Inhibitors. ACS Omega, 2017, 2, 1563-1575.	1.6	18
10	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 6643-6655.	2.9	12
11	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. Journal of Medicinal Chemistry, 2017, 60, 8801-8815.	2.9	7
12	Targeting Her2-insYVMA with Covalent Inhibitorsâ€"A Focused Compound Screening and Structure-Based Design Approach. Journal of Medicinal Chemistry, 2020, 63, 11725-11755.	2.9	7
13	RASPELD to Perform Highâ€End Screening in an Academic Environment toward the Development of Cancer Therapeutics. ChemMedChem, 2018, 13, 2065-2072.	1.6	5
14	Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.. Journal of Clinical Oncology, 2019, 37, e14718-e14718.	0.8	1